When you’ve been taking a biologic drug for years - maybe for rheumatoid arthritis, psoriasis, or Crohn’s disease - switching to a biosimilar can feel scary. You’re not just changing pills. You’re changing the very medicine your body has learned to rely on. But here’s the truth: biosimilar switching isn’t a gamble. It’s backed by science, real-world data, and millions of patient experiences.
What Exactly Is a Biosimilar?
A biosimilar isn’t a generic. Generics are exact copies of small-molecule drugs like aspirin or metformin. Biosimilars are copies of complex biologic drugs - proteins made from living cells. Think infliximab, adalimumab, etanercept. These aren’t made in a lab with chemicals. They’re grown in bioreactors using living cells. Because of that, no two batches are exactly alike, even from the same manufacturer. A biosimilar must prove it’s highly similar to the original (called the originator) in structure, function, safety, and effectiveness. Regulatory agencies like the FDA and EMA require over 250 analytical tests to confirm this. They also look at how the drug behaves in the body - absorption, how long it lasts, how it triggers immune responses. And they require clinical trials showing no meaningful difference in outcomes. The first U.S. biosimilar, Zarxio (filgrastim-sndz), got approved in 2015. Since then, 37 have been approved, mostly targeting inflammatory diseases. The big ones? Infliximab and adalimumab biosimilars. Together, they make up about 70% of all biosimilar use.What Happens When You Switch?
Switching means stopping your originator drug and starting the biosimilar. It can happen for two reasons:- Medical switching: Your doctor decides it’s right for you - maybe because the biosimilar is cheaper, or you’re having side effects.
- Non-medical switching: Your insurance or pharmacy forces the change to cut costs. You didn’t ask for it. You might not even know it’s happening until you get a new prescription.
Why Do Some People Stop Taking It?
If the science says it’s safe, why do 4% to 18% of patients quit after switching? It’s rarely because the drug stopped working. It’s because they felt like it did. A 2021 study in Frontiers in Psychology found that 32.7% of patients reported new or worsening symptoms after switching - even when lab tests showed no change. This is called the nocebo effect: expecting something bad makes you feel it. Reddit threads are full of stories: “I switched to the biosimilar and my joints started aching again.” “My skin flared up - I just knew it wasn’t working.” But when doctors checked their drug levels and inflammation markers? Everything was normal. Other reasons for stopping:- Injection site reactions - redness, itching, swelling. Happens in about 7.8% of adalimumab biosimilar users.
- Confusion - “I used to get this in a pen. Now it’s a vial. Is this the same?”
- Loss of trust - “My doctor didn’t explain this. I feel like a lab rat.”
What About Switching Between Biosimilars?
Some patients switch from originator to biosimilar, then later to a different biosimilar. Is that safe? Yes - but it’s less studied. The NOR-SWITCH II study tracked patients who switched multiple times. After two years, 89.2% were still on therapy. No safety red flags. But not all studies agree. One Spanish study found a higher discontinuation rate (15.3%) after switching from CT-P13 to SB2 in IBD patients compared to historical controls. Yet, drug levels stayed the same. So again - the drug worked. The patient just stopped. Experts say: If you’re stable, switching between biosimilars is fine. If your disease is active or you’ve had bad reactions before, proceed with caution.The Cost Factor - Why This Matters
Biosimilars cost 15% to 35% less than the originator. In 2023, Humira biosimilars launched at a 35% discount. That’s billions saved for insurers and patients. By 2023, 85% of U.S. health plans had mandatory switch policies. That means if you’re on Humira, your insurer will push you to switch - whether you want to or not. That’s good for the system. But bad if you’re not prepared. The PERFUSE study showed that when patients got a 20-minute counseling session before switching, discontinuation dropped from 18% to just 6.4%. Simple. Clear. Human.What Should You Do If You’re Asked to Switch?
Don’t panic. Don’t say yes or no right away. Do this:- Ask why. Is this your doctor’s recommendation? Or your insurer’s rule?
- Ask for data. “Can you show me studies on this switch?”
- Ask about monitoring. Will you check my drug levels? My disease activity? In 3 months?
- Ask for time. Can you give me a trial period? What if I feel worse?
- Ask for support. Will I get a nurse or pharmacist to walk me through the injection?
Regulations: FDA vs. EMA
The rules aren’t the same everywhere. In Europe (EMA), any approved biosimilar can be switched freely. No special permission needed. In the U.S. (FDA), there’s a special designation: “interchangeable.” Only biosimilars with this label can be swapped at the pharmacy without the doctor’s approval. Cyltezo became the first interchangeable adalimumab biosimilar in 2024. That means in some states, you might get switched without even knowing. In others, your doctor must sign off. This patchwork makes it confusing. But the science doesn’t change. Safe switching is possible - if you’re informed.Long-Term Outlook
The global biosimilar market hit $26.3 billion in 2022. It’s growing at over 20% a year. Why? Because over $178 billion in biologic patents are expiring by 2025. More biosimilars = more choices = lower prices. But the real win isn’t cost. It’s access. Before biosimilars, many patients couldn’t afford these life-changing drugs. Now, they can. The challenge? Making sure patients aren’t scared into quitting.Final Take
Switching from an originator biologic to a biosimilar isn’t risky. It’s smart. The data is clear: efficacy stays the same. Safety stays the same. Quality stays the same. What changes? The price. And sometimes, your peace of mind. If you’re being asked to switch - and you’re stable - say yes. But don’t do it blind. Ask questions. Get support. Know what to watch for. Your body doesn’t care if the drug came from Pfizer or Amgen. It only cares if it works. And it will.Is biosimilar switching safe for patients with inflammatory bowel disease?
Yes. Multiple studies, including one published in PMC9485085, show that switching from originator infliximab to its biosimilar (CT-P13) or from one biosimilar to another (CT-P13 to SB2) maintains clinical remission in over 90% of IBD patients. Drug levels, inflammation markers like fecal calprotectin, and immune responses remain stable. Discontinuation is rare and usually linked to psychological factors, not drug failure.
Can I switch back to the originator if I don’t feel well after switching?
Yes. Most doctors will allow you to switch back if you report new or worsening symptoms - even if lab tests show no change. Many patients feel better psychologically after returning to the originator, which can improve outcomes. But if your symptoms are truly due to the drug failing, switching back won’t help. That’s why monitoring drug levels and disease activity is key.
Why do some patients report side effects after switching to a biosimilar?
Most side effects reported after switching - like joint pain, fatigue, or skin flares - aren’t caused by the drug itself. They’re the nocebo effect: the mind expecting trouble creates symptoms. Studies show 32.7% of patients report new issues after switching, yet objective measures show no change. Injection site reactions are real and occur in about 7-8% of cases, but these are mild and temporary.
Are biosimilars as effective as the original biologics for rheumatoid arthritis?
Yes. Clinical trials and real-world data from the NOR-Switch study and others show no meaningful difference in effectiveness for RA patients switching from originator infliximab or adalimumab to their biosimilars. Disease activity scores (DAS28), joint swelling, and pain levels remain unchanged. Retention rates stay above 85% at one year.
What’s the difference between a biosimilar and a generic drug?
Generics are exact chemical copies of small-molecule drugs like ibuprofen. Biosimilars are highly similar - but not identical - copies of large, complex proteins made from living cells. Because biologics are made in living systems, they can’t be replicated exactly. Biosimilars must prove similarity through hundreds of tests and clinical trials, while generics only need to prove bioequivalence.
Does switching to a biosimilar increase the risk of immunogenicity?
No. Studies tracking immunogenicity - the body making antibodies against the drug - show no increase after switching. The Lauret et al. 2022 study found only 3 cases of anti-drug antibodies per 100 patient-years during multiple switches. Trough levels remained stable, and adverse events didn’t rise. Immunogenicity is more tied to the disease and individual immune response than the drug brand.
Why do some countries allow automatic pharmacy substitution while others don’t?
The U.S. FDA allows automatic substitution only for drugs labeled “interchangeable,” which requires extra studies proving switching won’t reduce safety or effectiveness. The EMA doesn’t require this - they assume all approved biosimilars are switchable. This leads to different practices: in Europe, pharmacists can swap freely. In the U.S., it depends on state laws and whether the biosimilar has the interchangeable designation.
Can I switch from one biosimilar to another biosimilar?
Yes, and evidence supports it. The NOR-SWITCH II extension showed 89.2% retention after multiple switches over 24 months. Studies switching from CT-P13 to SB2 or SB4 to GP2015 found no significant drop in effectiveness or increase in adverse events. However, each switch should be monitored closely, especially in patients with unstable disease or prior reactions.
Write a comment